Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. Observational registry

Affiliations

• ¹ Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Clinical Pharmacology and Toxicology, Germany. reinhold.kreutz@charite.de.
• ² Department of Nephrology, Pitié-Salpêtrière University Hospital, Paris, France.
• ³ Division of Nephrology and Clinical Immunology, RWTH Aachen University Hospital, Germany.
• ⁴ University Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria.
• ⁵ B Braun Medical Care AG Dialysezentrum Hochfelden, Zürich, Switzerland.
• ⁶ Department of Neurology, Universitätsspital Zürich, Switzerland and Cereneo Center for Neurology and Rehabilitation, Vitznau, Switzerland.
• ⁷ Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für vegetative Physiologie.
• ⁸ Thrombosis Research Unit, Department of Medicine I, Division Haematology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.